Why the study?
What is the incidence of peripheral edema and associated withdrawal rate with calcium channel blocker therapy?
What is the incidence of peripheral edema and associated withdrawal rate with calcium channel blocker therapy?
Peripheral edema is a clinically significant adverse effect of calcium channel blockers that leads to treatment discontinuation in over 5% of patients, though risk can be mitigated by using non-dihydropyridines or lipophilic dihydropyridines.
>5% long-term CCB discontinuation from edema warrants non-DHP or lipophilic DHP selection; extends meta-analytic tolerability data for agent choice.
The incidence of peripheral edema progressively increased with duration of CCB therapy up to 6 months. Over the long term, more than 5% of patients discontinued CCBs because of this adverse effect. Edema rates were lower with both non-DHPs and lipophilic DHPs.
No takes yet. Share an insight, caveat, or question.
Makani et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: